Stolarz AJ, et al. - Using administrative claims data, researchers conducted a nested case-control study of adult female breast cancer patients receiving an antihypertensive agent to ascertain if the use of calcium channel blockers is associated with the risk of lymphedema among these patients. Patients with lymphedema comprised the cases (n = 717); these were matched to five controls based on nest entry date (±180 days), age (± 5 years), number of hypertensive drug classes, Charlson Comorbidity Index, thiazide exposure, and insurance type (n = 1,681). The adjusted analysis suggested a significant association of calcium channel blockers exposure with increased risk of lymphedema. in breast cancer patients CCBs should be avoided or used with caution to lower the risk of developing lymphedema.